Veraxa Biotech AG VRXA
0.95 USD -0.04 (-4.04%)
At closeNov 4, 2026, 4:00 PM EST
0.99 +0.04 +4.21%
After hours · Nov 4, 4:00 PM ET
0.95 Day range 1.02
0.95 52-week range 27.36
- YTD
- -91.10%
- 1 year
- -90.97%
- Market cap
- 134.34M
- EPS (ttm)
- -0.57
- YTD return
- -91.10%
- 1-year return
- -90.97%
- Volume
- 103.12K
- Avg volume
- 257.07K
- Open
- 0.9901
- Previous close
- 0.99
- Day's range
- 0.95 – 1.02
- 52-week range
- 0.95 – 27.36
2Y -9.0848 (-90.49%)
Financials — quick view
VRXA Revenue — quarterly 23.43K
VRXA Net income — quarterly -75.72M
VRXA EPS — quarterly -4.89
News
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress 
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? 
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy 
12 Health Care Stocks Moving In Friday's Intraday Session 
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer 
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency 
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates 
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery 
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb 
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
Your note
Sign in to keep a note on VRXA — it syncs with the Stock Master app.